Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

7,807 total articles

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

SAB Biotherapeutics, listed on Nasdaq as SABS, announced upcoming oral and poster presentations highlighting new clinical and mechanistic data on SAB-142, their lead immunotherapy candidate for newly diagnosed Stage 3 type 1 diabetes (T1D). The data showcase SAB-142's multi-specific binding profile and potential as a best-in-class disease-modifying…

Rezolve Ai Appoints James House to Lead Reward, Strengthening Its Global AI-Powered Banking and Commerce Platform

Rezolve Ai Appoints James House to Lead Reward, Strengthening Its Global AI-Powered Banking and Commerce Platform

Rezolve Ai has appointed James House as CEO of Reward, its recently acquired banking and commerce media business. House's extensive experience at Mastercard and BNP Paribas positions him to scale Reward's international footprint and expand its offerings within the AI-driven commerce ecosystem. The move supports Rezolve Ai's strategy to unify bankin…

Dime Announces Significant Hires to Advance Growth Plan

Dime Announces Significant Hires to Advance Growth Plan

Dime announced several significant executive and managerial hires from prominent banks such as Flagstar and Metropolitan Commercial Bank, adding approximately 22 bankers in total. These hires include leadership roles aimed at driving growth in multiple New York and New Jersey markets, along with the establishment of a new Equipment and Franchise Fi…

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics announced the publication of preclinical data in Nature Communications for ALLO-329, an investigational allogeneic dual-targeted CD19/CD70 CAR T therapy aimed at treating autoimmune diseases such as lupus, myositis, and scleroderma. The data demonstrate enhanced CAR T cell expansion, persistence, and efficacy through the Dagge…

Xenon to Present at Upcoming Investor Conferences

Xenon to Present at Upcoming Investor Conferences

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, announced its participation in four upcoming investor conferences during the second quarter of 2026, aiming to present its pipeline progress and strategic outlook to investors and stakeholders.

Mount Logan Capital Inc. to Participate in the B. Riley Securities, Inc. 2026 Annual Investor Conference

Mount Logan Capital Inc. to Participate in the B. Riley Securities, Inc. 2026 Annual Investor Conference

Mount Logan Capital Inc. will participate in the B. Riley Securities 2026 Annual Investor Conference held on May 20-21, 2026, in Marina del Rey. The company's executive team will hold investor meetings to discuss their integrated alternative asset management and insurance solutions business, emphasizing their approach to generating durable, fee-bas…

Runway Growth Finance Corp. Announces Date for First Quarter 2026 Financial Results and Conference Call

Runway Growth Finance Corp. Announces Date for First Quarter 2026 Financial Results and Conference Call

Runway Growth Finance Corp., a Nasdaq-listed specialty finance company providing flexible capital solutions to late- and growth-stage companies, will release its first quarter 2026 financial results after market close on May 7, 2026, followed by a conference call to discuss the results. The company is externally managed by an affiliate of BC Partne…

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines, a clinical-stage oncology firm focusing on RAS-addicted cancer therapies, announced an increase in its concurrent public offerings to raise approximately $2 billion. The offerings include about 10.56 million shares of common stock priced at $142 per share (up from $750 million to $1.5 billion) and $500 million in 0.5% converti…

Progressive Reports March 2026 Results

Progressive Reports March 2026 Results

The Progressive Corporation reported solid financial results for March 2026 and the first quarter, showing growth in net premiums written by 10% for the month and 6% for the quarter. Net income increased by 36% in March and 10% for the quarter compared to the previous year. The combined ratio improved slightly for the month but was flat for the qua…

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL, Inc. has rescheduled its shareholder update conference call to April 23, 2026 to provide updates on its potential transaction with Celularity Inc. The company announced it will not finance the transaction under its previous agreement and is negotiating a new financing structure with another investor group. Details on the transaction and fin…

T3 Defense Announces Unaudited Preliminary Key Financial and Operational Metrics for Q1 2026, Its First Reporting Quarter as a Defense-Focused Holding Company

T3 Defense Announces Unaudited Preliminary Key Financial and Operational Metrics for Q1 2026, Its First Reporting Quarter as a Defense-Focused Holding Company

T3 Defense Inc. announced its unaudited preliminary financial and operational results for Q1 2026, the company's first full quarter operating as a defense-focused holding company. The company expects Q1 revenue of approximately $4.2 million and confirms its full-year 2026 revenue guidance of $26 million, supported by a robust backlog of over $12 mi…

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Achieve Life Sciences announced the successful transfer of cytisinicline manufacturing technology to US-based Adare Pharma Solutions, including completion of analytical method transfer and production of the first engineering batch. Despite previous FDA cGMP inspection concerns at the former facility, Achieve plans to resubmit its NDA with Adare as …

Reviva Announces Letter to Shareholders

Reviva Announces Letter to Shareholders

Reviva Pharmaceuticals provided an update to shareholders detailing its recent $10 million financing to strengthen cash reserves, plans to extend the patent life of its lead drug candidate brilaroxazine through a new formulation, and preparations to initiate a second Phase 3 schizophrenia trial (RECOVER-2). The company seeks FDA alignment on the ne…